Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel

Next Previous
Trial Profile

A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IOV 3001 (Primary) ; Lifileucel
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Iovance Biotherapeutics

Most Recent Events

  • 27 Feb 2025 Status changed from planning to recruiting.
  • 15 May 2024 New trial record
  • 09 May 2024 According to an Iovance Biotherapeutics media release, company plans to submit an Investigational New Drug application (IND) for a Phase 1/2 clinical trial of IOV-3001 in the third quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top